The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | 7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, presents 7-year follow-up data from a Phase II study on fixed-duration obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia (CLL). The study reports a median progression-free survival (PFS) of 81.8 months for relapsed/refractory (R/R) patients and 88.5 months for treatment-naive patients. Interestingly, there was no association between measurable residual disease (MRD) status and PFS. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
